Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.

Huang, Shang-Yi

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. [electronic resource] - Annals of hematology Aug 2014 - 1371-80 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1432-0584

10.1007/s00277-014-2063-7 doi


Adaptor Proteins, Signal Transducing
Aged
Angiogenesis Inhibitors--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bone Marrow Examination--methods
Boronic Acids--administration & dosage
Bortezomib
Dexamethasone--administration & dosage
Female
Follow-Up Studies
Gene Expression Profiling
Humans
Lenalidomide
Male
Melphalan--administration & dosage
Middle Aged
Multiple Myeloma--drug therapy
Neoplasm Proteins--analysis
Neoplastic Stem Cells--chemistry
Paraffin Embedding
Peptide Hydrolases--analysis
Prednisolone--administration & dosage
Pyrazines--administration & dosage
Salvage Therapy
Survival Analysis
Syndecan-1--analysis
Thalidomide--administration & dosage
Treatment Outcome
Ubiquitin-Protein Ligases